DES and DCB with Similar Results in Femoropopliteal Artery Disease

Courtesy of Dr. Carlos Fava.

Nowadays, peripheral interventions are on the rise and the technological development of stents and balloons would help achieve better outcomes. Both drug-eluting stents (DES) and drug-coated balloons (DCB) have proved to be beneficial for femoropopliteal interventions, but the actual role of each of these technologies remains unclear.

DES de 2.0 mm para vasos muy pequeños: ¿Es viable?This prospective, randomized 1:1 study included 15 patients with intermittent claudication, femoropopliteal lesions, and Rutherford functional categories 2 to 5.

 

The devices used were the Zilver PTX platform stent (Cook Medical) and the In.Pact Admiral or In.Pact Pacific balloon (Medtronic Vascular).

 

Patient characteristics between groups were similar: the mean age was 69; 24% of patients had diabetes; most were classified as category 2-3; 20% had renal insufficiency; lesion length was 150 mm, and half the patients had total occlusions.


Read also: AHA 2018 | New-Generation DES Are Similar to Second-Generation DES Beyond Polymer.


In the DCB group, the bailout was 25%. Additionally, ≥30% residual lesions were also more frequent in that group.

 

Primary patency at 12 months was similar between groups (79.9% DEB, 79.3% DES; rate difference 0.6%; 95% confidence interval [CI]: 13% to 14.2%; p = 0.96) and there was a trend in favor of DES at 3 years. There were no differences as regards mortality or amputations. Improvement was similar for both groups.

 

Conclusion

Patency at 12 months, effectiveness, and safety of DES versus DCB plus bailout stenting in femoropopliteal interventions are comparable. There was a trend in favor of DES over DCB at 36 months.

 

Courtesy of Dr. Carlos Fava.

 

Original title: Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients with Femoropopliteal Arterial Disease.

Reference: Yvonne Bausback et al. J Am Coll Cardiol 2019;73:667-79.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...